31.97MMarket Cap-1803P/E (TTM)
1.695High1.670Low4.91KVolume1.670Open1.650Pre Close8.23KTurnover0.04%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.96P/B20.04MFloat Cap0.42052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM1.53%Amplitude0.420Historical Low1.675Avg Price1Lot Size
Chemomab Therapeutics Stock Forum
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024.
The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 w...
1 min ago
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Resale of up to 8.1 Mln Adss
No comment yet